Erich Hunziker
Since July 2019 Dr. Erich Hunziker is the Chairman of NovImmune.
Erich Hunziker
He previously served as CFO of Roche from 2001 to 2010 and as Chairman of the Board of Directors of BB Biotech AG until 2023. From 1983 to 2001 he held various executive positions at Corange, Boehringer Mannheim and at Diethelm-Keller-Group (DKSH), where he ultimately served as CEO.
In 2013 he was the seed investor to support EngMab AG, which successfully developed a BCMA-bispecific Antibody: EngMab was sold to Celgene in 2016.
Dr. Erich Hunziker is Chairman of Entsia International AG and a co-founder and Chairman of the LamKap Bio group. He is also Chairman of the discoveric bio group and of discoveric marketplace since 2019 and 2020, respectively.
Dr. Erich Hunziker earned a Ph.D. in Industrial Engineering from the Swiss Federal Institute of Technology in Zurich.
Holger Blum
Since July 2019 Holger Blum is a Board Member of NovImmune.
Holger Blum
Since July 2019 Holger Blum is a Board Member of NovImmune.
Holger Blum is founding partner of Patinex Management AG, which provides consulting and advisory services for family offices, corporates and banks. More than 20 years ago he started his career as sell-side healthcare analyst at Deutsche Bank and got voted no 1 in European Biotech and Medtech Research in the Institutional Investor Survey in several years.
In 2014 he became partner of BZ Bank and was in charge of private and public healthcare investments. As such he represented the interests of NovImmune`s majority shareholder and was instrumental in the split and divestment of certain NovImmune assets to Sobi.
Holger Blum graduated with an MBA degree from the University of Mannheim, Germany and Western Illinois University in Macomb, USA.
